Zepbound and Wegovy are approved for weight loss and weight management, while Mounjaro is not. But doctors may prescribe Mounjaro off-label for this purpose. (Off-label use means a drug is ...

Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

When the Food and Drug Administration (FDA) approved Byetta (exenatide) in 2005, doctors thought it was just approving the ...

Wilde is getting more, and better, sleep now that his sleep apnea is under control, thanks to his CPAP machine and tirzepatide. Also known as Zepbound or Mounjaro, it's the same drug helping millions ...

Indian market for these drugs has grown to nearly Rs 600 crore and is expected to keep growing. Weight-loss drugs are ...

If you’re struggling with weight, you’re not alone. Around 42 percent of American adults have obesity. In addition to ...

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of treatment Tirzepatide users experienced greater waistline reduction (7.2 ...

About SURMOUNT-5 SURMOUNT-5 (NCT05822830) was a 72-week, multi-center, randomized, open-label ... as Mounjaro for adults with type 2 diabetes to improve glycemic control, and as Zepbound ...

“Mounjaro is indicated as an adjunct to diet ... Hair loss is included in the Zepbound label,” they added, before including a note about ZEPBOUND-treated patients, who were associated with ...

SURMOUNT-5 (NCT05822830) was a 72-week, multi-center, randomized, open-label, Phase 3b trial evaluating ... related comorbid condition. Both Mounjaro and Zepbound should be used in combination ...

Mounjaro. Ozempic. Wegovy. Zepbound. All these are brand names linked in some way to diabetes and weight loss-or, as the President of the United States, Donald Trump, refers to it, the "fat shot" ...